AG2R LA Mondiale Gestion D Actifs Has $7.46 Million Stock Position in Merck & Co., Inc. $MRK

AG2R LA Mondiale Gestion D Actifs increased its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 0.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,279 shares of the company’s stock after purchasing an additional 809 shares during the period. AG2R LA Mondiale Gestion D Actifs’ holdings in Merck & Co., Inc. were worth $7,463,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Little House Capital LLC boosted its position in shares of Merck & Co., Inc. by 1.2% during the second quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after purchasing an additional 308 shares in the last quarter. Semus Wealth Partners LLC grew its stake in Merck & Co., Inc. by 8.2% in the first quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock valued at $452,000 after acquiring an additional 382 shares during the period. Longfellow Investment Management Co. LLC increased its holdings in shares of Merck & Co., Inc. by 20.4% in the first quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after acquiring an additional 3,282 shares in the last quarter. Quilter Plc increased its holdings in shares of Merck & Co., Inc. by 5.6% in the first quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after acquiring an additional 62,933 shares in the last quarter. Finally, MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH raised its position in shares of Merck & Co., Inc. by 9.8% during the second quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 888,415 shares of the company’s stock worth $70,327,000 after purchasing an additional 79,529 shares during the period. Institutional investors and hedge funds own 76.07% of the company’s stock.

Wall Street Analyst Weigh In

MRK has been the subject of several research analyst reports. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Monday, October 13th. They issued a “neutral” rating and a $95.00 price objective for the company. Wells Fargo & Company reduced their price target on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a report on Wednesday, July 30th. Berenberg Bank lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $100.00 to $90.00 in a report on Wednesday, September 17th. Morgan Stanley cut their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $104.33.

Merck & Co., Inc. Trading Up 0.4%

Merck & Co., Inc. stock opened at $87.54 on Friday. The firm has a 50-day moving average of $84.43 and a 200-day moving average of $81.54. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $106.49. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.42 and a quick ratio of 1.17. The company has a market cap of $218.65 billion, a price-to-earnings ratio of 13.49, a P/E/G ratio of 0.96 and a beta of 0.37.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 EPS for the quarter, beating the consensus estimate of $2.03 by $0.10. The firm had revenue of $15.81 billion during the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. On average, equities analysts expect that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.